INNOPRAN XL (propranolol hydrochloride) by ANI Pharmaceuticals is established. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 13h ago
INNOPRAN XL is an extended-release oral capsule formulation of propranolol hydrochloride, a non-selective beta-blocker used to treat hypertension and other cardiovascular conditions. It works by decreasing cardiac output, inhibiting renin release, and reducing sympathetic nerve outflow to lower blood pressure. The mechanism is well-established with decades of clinical experience.
Product approaching loss of exclusivity with modest Medicare spending signals contraction phase; brand team size likely stable to shrinking.
established. Among factors that contribute to the antihypertensive action are: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Worked on INNOPRAN XL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
INNOPRAN XL roles are concentrated in defensive commercial management and customer relationship preservation as the product approaches LOE. Career opportunities focus on cost optimization, market access, and managing generic transition rather than growth or innovation.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo